Crechek 5 mg (Rosuvastatin Calcium)

Adult dose

For patients with primary hypercholesterolemia, mixed hyperlipidemia, dysbetalipoproteinemia, and homozygous familial hypercholesterolemia, the recommended dosage is 5 mg once daily, regardless of meal timing. For those needing greater LDL-cholesterol reduction, the maintenance dosage can be adjusted up to 10 mg once daily, with the dosage increased to a maximum of 20 mg once daily based on patient response at intervals of 4 weeks or more.

Child dose

The usual dosage for pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17) is between 5 mg to 20 mg once daily, with the dosage adjusted according to individual treatment goals at intervals of 4 weeks or more.

This medication should not be used in certain patients. For example, individuals who are allergic to this medication, those with severely impaired liver function, those with muscle diseases, those taking certain immunosuppressants, individuals with severe renal impairment, pregnant or nursing women, and those with genetic issues such as lactose intolerance should not take this medication. Moreover, caution is warranted for patients with a history of excessive alcohol consumption or liver disease, and regular liver function tests should be conducted before and during treatment. In cases of conditions like hypothyroidism or nephrotic syndrome, it is advisable to treat those conditions before taking this medication. Myalgia or myopathy may occur during the use of this medication, and if any unusual muscle symptoms occur, medical personnel should be notified immediately. Especially if muscle-related symptoms coincide with significantly elevated muscle enzyme levels in blood tests, discontinuation of this medication is warranted. This medication may increase blood concentration when taken with certain drugs, raising the risk of muscle-related side effects. Therefore, if other medications are being taken, medical personnel must be informed. Special caution is required when used in conjunction with certain antivirals, immunosuppressants, and fibrate drugs. Women who are pregnant or may become pregnant must use appropriate contraception before taking this medication, and if pregnancy is confirmed, it should be discontinued immediately. Additionally, it is safer for nursing mothers to avoid this medication. In cases of overdose, there are no specific antidotes, so management based on symptoms and monitoring liver function and muscle enzymes is necessary. This medication is generally known not to significantly affect driving or machinery operation; however, caution is still advised as dizziness may occur infrequently. Finally, it is important to regularly monitor liver function and muscle condition during treatment with this medication, and to consult with medical personnel immediately if any unusual symptoms occur.

Serious side effects

Allergic reactions, including urticaria and angioedema, chest tightness, difficulty breathing, respiratory distress, jaundice, severe muscle weakness, ophthalmoplegia, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, rhabdomyolysis, immune-mediated necrotizing myopathy, acute renal failure, oliguria, fatal and non-fatal liver failure

Mild side effects

• Headache
• dizziness
• constipation
• nausea
• abdominal pain
• itching
• rash
• myalgia
• weakness
• hematuria

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be kept between 1 and 30 degrees Celsius at room temperature, and it is advisable to avoid excessively hot or cold places.

Appearance

Yellow round film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle